2007

Wyeth Begins Marketing and Distributing BeneFIX in Europe 

New Program from NACCHO Empowers Youths and Teens Through Challenging and Adventurous Fun 

Wyeth Pharmaceuticals Introduces Its First Training Kit to Help People with Hemophilia Learn Self-Infusion Techniques 

NACCHO / Wyeth Cup Awarded to Camp NJoyItAll for Team-Building Program for Teens 

Wyeth Pharmaceuticals Awards $100,000 in Academic Scholarships to Students from the Hemophilia Community 

CDC Selects New Sites for Pilot Study of Inhibitors in Hemophilia 

Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX 

Wyeth Pharmaceuticals Extends ReFacto Trial Prescription Program into 2007  

Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies 

Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies 

2006

Wyeth Pharmaceuticals Awards $100,000 in Scholarships to the Hemophilia Community 

Wyeth Pharmaceuticals Increases Funding for Arts Program for Children with Bleeding Disorders and Their Families 

Wyeth Pharmaceuticals Initiates Ninth Year of Supporting Bleeding Disorder Summer Camps 

Wyeth Pharmaceuticals Pilots Rapid Response Service to Provide Patient Access to Hemophilia Factor VIII & IX Products in Emergency Situations 

World Federation of Hemophilia Twinning Program Receives Sixth Consecutive Year of Funding from Wyeth Pharmaceuticals 

Scoring for Care: The World Federation of Hemophilia's Fundraising To Provide Hemophilia Treatment for All 

Wyeth Pharmaceuticals Donates Funds to the World Federation of Hemophilia and the Canadian Hemophilia Society 

Pharmacokinetic Study Confirms Comparability of ReFacto^® Antihemophilic Factor (Recombinant) to Leading Factor VIII Therapy 

Wyeth Pharmaceuticals Introduces the 2006 ReFacto^® Antihemophilic Factor (Recombinant) Trial Prescription Program 

These documents are in PDF (portable document format). PDF files require Adobe® Reader®; click here to download this free program.

National Hemophilia Foundation Expands First Step Train-the-Trainer Program

NACCHO / Wyeth Cup Awarded to Camp Ailihpomeh for Outstanding CIT Program

2005

Wyeth Pharmaceuticals Donates Funds to the World Federation of Hemophilia and the Haemophilia Foundation of Australia - August 2005

Wyeth Pharmaceuticals Awards $97,500 in Scholarships to the Hemophilia Community - August 2005

Wyeth Pharmaceuticals Initiates Clinical Trial of Investigational Albumin-Free Recombinant Drug for Hemophilia A - August 2005

Wyeth Pharmaceuticals Donates Hemophilia Educational Program to the World Federation of Hemophilia - July 2005

Wyeth Pharmaceuticals Donates Hemophilia Products to Summer Camps - June 2005

Wyeth Pharmaceuticals Introduces "Living with Hemophilia" Speakers Bureau for the Hemophilia Community - June 2005

Wyeth Pharmaceuticals Introduces Innovative Hemophilia Program to Address Insurance Coverage Concerns - June 2005

Wyeth Pharmaceuticals to Remain Sole Sponsor of the World Federation of Hemophilia Twinning Program for the Fifth Consecutive Year - May 2005

Wyeth Pharmaceuticals Introduces the 2005 ReFacto^® Trial Prescription
Program - May 2005

CDC Foundation Announces $3 million Grant to Fund Hemophilia Study - March 2005

2004

Wyeth Pharmaceuticals Donates Funds to the World Federation of Hemophilia and the Hemophilia Society of Thailand - December 2004

Hemophilia Solutions - Special Issue

ReFacto^® Antihemophilic Factor (Recombinant) R2 Kit Now Available - November 2004

Hemophilia Solutions - September 2004

Second BeneFIX Manufacturing Facility Receives Regulatory Approval - May 2004

ReFacto^® Manufacturing Consolidated to Stockholm, Regulatory Applications for Investigational Drug Delayed While New Manufacturing Information Filed-January 2004

2003

Hemophilia Solutions: NHF's 55th Annual Meeting "Many Stories, One Voice"- Issue Seven, October 2003

Hemophilia Solutions: New Assay Standard for ReFacto^® Approved by the FDA-Issue Six, July 2003

Hemophilia Solutions: New Assay Standard for ReFacto: What Does This Mean to Patients?-Issue Five, June 2003

Indication
BeneFIX is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings. BeneFIX is not indicated for the treatment of other factor deficiencies (eg, factors II, VII, VIII and X) nor the treatment of hemophilia A patients with inhibitors to factor VIII, nor the reversal of coumarin-induced anticoagulation, nor the treatment of bleeding due to low levels of liver-dependent coagulation factors.

Important Safety Information

	•	As with the intravenous administration of any protein product, common adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, or tiredness.
	•	BeneFIX may be contraindicated in patients with a known history of hypersensitivity to hamster protein.
	•	Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. Patients should be informed of the early symptoms and signs of hypersensitivity reactions. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any hypersensitivity reactions occur.

Please see BeneFIX Prescribing Information

Indication
ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

Important Safety Information

	•	As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions.
	•	The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto.
	•	Allergic reactions such as hives, itching, difficulty breathing, rapid heart rate, light-headedness and anaphylaxis have been reported for all factor VIII products. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any of these symptoms occur.

Please see ReFacto Prescribing Information

The health information contained herein is provided for educational purposes only and is not meant to replace personal discussions between health care providers and patients. All decisions about patient care must be made with a health care provider who can assess the special needs of each individual patient.